Biotech major Gilead Sciences Inc. GILD is slated to report third-quarter 2019 results on Oct 24, after market close.
Gilead has a pretty decent track record, with earnings beating estimates in three of the last four quarters, the average being 2.20%. In the last reported quarter, the company’s earnings beat expectations by 4.60%.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,